Logo from CREIT

CEREIT net property income up 3.6% YoY to $48.9m in Q1

Its DPU showed resiliency despite falling 2.4% YoY in Q1.

SGX-listed Cromwell European REIT's (CEREIT) net property income grew 3.6% year-over-year (YoY) to €33.6m (S48.9m) in Q1 2023 from €32.5m ($47.2m) in Q1 2022 due to the 15.7% income growth in its light industrial/logistics sector.

In its bourse filing, CREIT's gross revenue increased 4.2% YoY to €54.8m ($79.6m) in Q1 2023 from €52.6m ($76.4m) in Q1 2022.

CEREIT attributed its sturdy operational performance to "active leasing and high occupancy, positive rent reversions and high annual inflation indexation in most leases."

READ MORE: Cromwell European Reit bags at least 50% pre-leasing commitment for Italy office

CEREIT's indicative distribution per unit (DPU) showed resiliency in the face of prolonged external macro and geopolitical changes over the last three years despite falling 2.4% YoY to 4.12 € cents in Q1 2023 from 4.22 € cents in Q1 2022.
 

Follow the link for more news on

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare